Articles tagged with: Revlimid
The initial results from three early-phase clinical trials suggest that the investigational drug MLN9708, either alone or in combination with Revlimid and dexamethasone, may be an effective treatment for both newly diagnosed multiple myeloma patients and patients with relapsed and/or treatment-resistant disease.
The findings from the three trials were presented earlier this week at the American Society of Hematology (ASH) annual meeting in San Diego.
The most recent results of a Phase 2 clinical trial indicate that elotuzumab in combination with Revlimid and dexamethasone is safe and effective in relapsed and refractory multiple myeloma patients.
Dr. Sagar Lonial from the Winship Cancer Institute at the Emory University School of Medicine in Atlanta presented the updated Phase 2 results at the American Society for Hematology (ASH) annual meeting in San Diego on Monday.
The preceding Phase 1 trial of elotuzumab showed that 82 percent of relapsed/refractory myeloma patients had a partial response or better to the drug …
Yesterday, the third day of the American Society of Hematology (ASH) 2011 Annual Meeting in San Diego, was the busiest day of the meeting for people interested in multiple myeloma. Myeloma-related presentations filled the entire morning and afternoon, and sometimes there were even multiple relevant presentations going on simultaneously.
The morning presentations about therapies combining current myeloma drugs will be covered in this update. Morning presentations about potential new myeloma therapies were covered in an update published earlier today, and presentations from the rest of the day will be …
Results from a number of multiple myeloma studies were presented yesterday during the second day of the American Society of Hematology (ASH) 2011 annual meeting in San Diego.
Predicting Response To Immunomodulatory Drugs
During an oral presentation and a poster presentation yesterday, researchers discussed the role of the protein cereblon in the treatment of myeloma. Results from one study (abstract) in myeloma cell lines suggested that cereblon plays a key role in whether multiple myeloma patients respond to the immunomodulatory drugs Revlimid (lenalidomide) and pomalidomide. Another study …
Results of a recent study show that newly diagnosed multiple myeloma patients initially treated with a combination of cyclophosphamide, Velcade, and dexamethasone have better response rates and less severe side effects than patients treated with Revlimid-dexamethasone or cyclophosphamide-Revlimid-dexamethasone.
The survival outcomes for the patients treated with cyclophosphamide, Velcade, and dexamethasone also are promising.
However, the difference in survival rates between the three treatment regimens is not statistically significant.
This is partly because “the numbers [of patients in the study] were too small to show differences in survival,” explained Dr. Craig Reeder …